



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

#56826

**Date:** July 08, 2025

**Subject:** Akoya Biosciences, Inc. - Contract Adjustment  
Option Symbol: 07/08/2025 - AKYA remains AKYA  
07/09/2025 - AKYA becomes QTRX1  
**Date:** 07/08/2025

**Contract Adjustment**

**Date:** July 8, 2025

**Option Symbol:** 07/08/2025 - AKYA remains AKYA (with adjusted deliverable described below)  
07/09/2025 - AKYA changes to QTRX1

**Strike Divisor:** 1

**Contracts Multiplier:** 1

**New Multiplier:** 100 (e.g., a premium of 1.50 yields \$150; a strike of 20 yields \$2,000.00)

**New Deliverable Per Contract:**

- 1) 14 Quanterix Corporation (QTRX) Common Shares (subject to adjustment)
- 2) Cash in lieu of 0.61 fractional QTRX Common Shares (subject to adjustment)
- 3) \$38.00 Cash (subject to adjustment)

Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

**CUSIP:** QTRX: 74766Q101

**Pricing**

Until the cash in lieu amount is determined, the underlying price for QTRX1 will be determined as follows if the terms are unchanged:

$$\text{QTRX1} = 0.1461 (\text{QTRX}) + 0.38$$

### **Delayed Settlement**

OCC will delay settlement of the QTRX component and the cash portion of the QTRX1 deliverable until the final merger consideration and cash in lieu of fractional QTRX shares are determined. Upon determination of the final merger consideration and the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate number of QTRX shares and the appropriate cash amount.

### **Background**

On July 7, 2025, Shareholders of Akoya Biosciences, Inc. (AKYA) voted concerning the proposed amended merger agreement with Quanterix Corporation (QTRX). The merger was approved and subsequently consummated before the open on July 8, 2025. As a result, each existing AKYA Common Share will be converted into the right to receive 0.1461 QTRX Common Shares plus \$0.38 Cash, subject to adjustment as described in the AKYA/QTRX Proxy Statement/Prospectus dated June 13, 2025. Cash will be paid in lieu of fractional QTRX shares.

### **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).